Cargando…

Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis

BACKGROUND: Rotavirus is one of the most common causes of infantile enteritis. In common enterocolitis, probiotic organisms, including Lactobacilli, are effective in treating diarrhea. A new species, Lactobacillus plantarum (LRCC5310), which was shown to inhibit the adherence and proliferation of ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Do Young, Yi, Dae Yong, Jo, Soojin, Lee, Yoo Min, Kim, Jong-Hwa, Kim, Wonyong, Park, Mi ri, Yoon, Seok min, Kim, Yunsik, Yang, Siyoung, Lim, In Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505315/
https://www.ncbi.nlm.nih.gov/pubmed/32957348
http://dx.doi.org/10.1097/MD.0000000000022192
_version_ 1783584784398680064
author Shin, Do Young
Yi, Dae Yong
Jo, Soojin
Lee, Yoo Min
Kim, Jong-Hwa
Kim, Wonyong
Park, Mi ri
Yoon, Seok min
Kim, Yunsik
Yang, Siyoung
Lim, In Seok
author_facet Shin, Do Young
Yi, Dae Yong
Jo, Soojin
Lee, Yoo Min
Kim, Jong-Hwa
Kim, Wonyong
Park, Mi ri
Yoon, Seok min
Kim, Yunsik
Yang, Siyoung
Lim, In Seok
author_sort Shin, Do Young
collection PubMed
description BACKGROUND: Rotavirus is one of the most common causes of infantile enteritis. In common enterocolitis, probiotic organisms, including Lactobacilli, are effective in treating diarrhea. A new species, Lactobacillus plantarum (LRCC5310), which was shown to inhibit the adherence and proliferation of rotavirus in the small intestine through animal experiments, was investigated for the efficacy and safety of patients with rotaviral enteritis. METHODS: LRCC5310 (Group I) and control (Group II) groups consisting of children who were hospitalized for rotaviral enteritis were compared, and the medical records of patients (Group III) who were hospitalized for rotaviral enteritis during the same study period were retrospectively analyzed. Clinical symptoms were compared and stool samples were collected to compare changes in virus multiplication between Groups I and II. RESULTS: Groups I, II, and III comprised 15, 8, and 27 children, respectively. There were no differences in clinical information among the groups at admission. In Group I, a statistically significant improvement was noted in the number of patients with diarrhea, number of defecation events on Day 3, and total diarrhea period as opposed to Group II (P = .033, P = .003, and P = .012, respectively). The improvement of Vesikari score in Group I was greater than that in the other groups (P = .076, P = .061, and P = .036, respectively). Among rotavirus genotypes, 9 (22.5%) strains and 8 (20.0%) strains belonged to the G9P8 and G1P8 genotypes, respectively. The virus reduction effect, as confirmed via stool specimens, was also greater in Group I. No significant side effects were noted in infants. CONCLUSION: LRCC5310 improved clinical symptoms, including diarrhea and Vesikari score, and inhibited viral proliferation in rotaviral gastroenteritis.
format Online
Article
Text
id pubmed-7505315
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-75053152020-09-24 Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis Shin, Do Young Yi, Dae Yong Jo, Soojin Lee, Yoo Min Kim, Jong-Hwa Kim, Wonyong Park, Mi ri Yoon, Seok min Kim, Yunsik Yang, Siyoung Lim, In Seok Medicine (Baltimore) 6200 BACKGROUND: Rotavirus is one of the most common causes of infantile enteritis. In common enterocolitis, probiotic organisms, including Lactobacilli, are effective in treating diarrhea. A new species, Lactobacillus plantarum (LRCC5310), which was shown to inhibit the adherence and proliferation of rotavirus in the small intestine through animal experiments, was investigated for the efficacy and safety of patients with rotaviral enteritis. METHODS: LRCC5310 (Group I) and control (Group II) groups consisting of children who were hospitalized for rotaviral enteritis were compared, and the medical records of patients (Group III) who were hospitalized for rotaviral enteritis during the same study period were retrospectively analyzed. Clinical symptoms were compared and stool samples were collected to compare changes in virus multiplication between Groups I and II. RESULTS: Groups I, II, and III comprised 15, 8, and 27 children, respectively. There were no differences in clinical information among the groups at admission. In Group I, a statistically significant improvement was noted in the number of patients with diarrhea, number of defecation events on Day 3, and total diarrhea period as opposed to Group II (P = .033, P = .003, and P = .012, respectively). The improvement of Vesikari score in Group I was greater than that in the other groups (P = .076, P = .061, and P = .036, respectively). Among rotavirus genotypes, 9 (22.5%) strains and 8 (20.0%) strains belonged to the G9P8 and G1P8 genotypes, respectively. The virus reduction effect, as confirmed via stool specimens, was also greater in Group I. No significant side effects were noted in infants. CONCLUSION: LRCC5310 improved clinical symptoms, including diarrhea and Vesikari score, and inhibited viral proliferation in rotaviral gastroenteritis. Lippincott Williams & Wilkins 2020-09-18 /pmc/articles/PMC7505315/ /pubmed/32957348 http://dx.doi.org/10.1097/MD.0000000000022192 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 6200
Shin, Do Young
Yi, Dae Yong
Jo, Soojin
Lee, Yoo Min
Kim, Jong-Hwa
Kim, Wonyong
Park, Mi ri
Yoon, Seok min
Kim, Yunsik
Yang, Siyoung
Lim, In Seok
Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title_full Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title_fullStr Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title_full_unstemmed Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title_short Effect of a new Lactobacillus plantarum product, LRCC5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
title_sort effect of a new lactobacillus plantarum product, lrcc5310, on clinical symptoms and virus reduction in children with rotaviral enteritis
topic 6200
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505315/
https://www.ncbi.nlm.nih.gov/pubmed/32957348
http://dx.doi.org/10.1097/MD.0000000000022192
work_keys_str_mv AT shindoyoung effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT yidaeyong effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT josoojin effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT leeyoomin effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT kimjonghwa effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT kimwonyong effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT parkmiri effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT yoonseokmin effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT kimyunsik effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT yangsiyoung effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis
AT liminseok effectofanewlactobacillusplantarumproductlrcc5310onclinicalsymptomsandvirusreductioninchildrenwithrotaviralenteritis